HARMONi-3 Clinical Trial Progress Update
"We provide the following updates for the global Phase III HARMONi-3 clinical trial: For the HARMONi-3 squamous cohort: Screening by investigators for patient enrollment in the squamous cohort of HARMONi-3 has been completed in the first quarter of 2026. We amended the study's statistical analysis plan and expect to conduct an interim analysis for progression free survival in the second quarter of 2026. Overall survival is expected to be immature at the time of the interim PFS analysis. We continue to expect to reach the prespecified number of events for the final PFS analysis, if applicable, in the second half of 2026. For the HARMONi-3 non-squamous cohort: Enrollment is currently expected to complete in the second half of 2026. We expect to reach the prespecified number of events for the final PFS analysis in the first half of 2027. Interim analyses for overall survival are planned to be conducted based upon reaching prespecified numbers of events."
